celgene_1_02

Celgene’s Otezla impresses at Phase 3 in scalp psoriasis

pharmafile | October 9, 2018 | News story | Manufacturing and Production, Research and Development |  Celgene, pharma, psoriasis 

Celgene has unveiled new Phase 3 data for Otezla (apremilast), its inhibitor of phosphodiesterase 4 (PDE4) specific for cyclic adenosine monophosphate (cAMP), in the treatment of moderate to severe scalp psoriasis, with users showing a “highly statistically significant” increase in Scalp Physician’s Global Assessment (ScPGA) response, achieving its primary endpoint.

Specifically, patients taking 30mg twice daily reported a ScPGA response of 0 or 1, representing clear or almost clear respectively, with at least a two-point reduction from baseline after 16 weeks, compared to placebo.

Over the same period, the second endpoint of the study reached statistical significance, represented by at least a four-point reduction on the whole body itching numeric rating scale (NRS) versus placebo.

“The scalp is the most commonly affected area in moderate to severe plaque psoriasis, impacting up to 80% of patients,” commented Terrie Curran, President of Celgene Inflammation and Immunology. “The area is difficult to treat with topical therapies, and clinical data from systemic therapies are limited. We are encouraged by the significant improvements in this trial and look forward to sharing these data to further enhance the Otezla label.”

Advertisement

Matt Fellows

Related Content

Pharma sees climate disruption as growing supply-chain risk

Nine in ten pharmaceutical companies across the UK and G7 countries expect climate-related disruption to …

AI in pharma: From lab development to patient impact

In the decade to 2025, AI use in vaccine development has increased markedly but is …

drug-trials

LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence

LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …

The Gateway to Local Adoption Series

Latest content